Stage III Ovarian Epithelial Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0028510 (Stage III Ovarian Epithelial Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00059787Erlotinib Plus Carboplatin and Paclitaxel in Ovarian CarcinomaTreatment